Temozolomide
Temodal
- Dosage form
- Tablet
- Available strengths
- 5 mg, 20 mg, 100 mg, 140 mg, 250 mg
- Drug class
- Alkylating antineoplastic agent (imidazotetrazine)
- Common brand
- Temodal
Clinical overview. Temozolomide (Temodal) is an oral alkylating chemotherapy capsule used to treat newly diagnosed glioblastoma multiforme alongside radiotherapy, and recurrent or progressive glioblastoma or anaplastic astrocytoma. It carries serious risks of bone marrow suppression and liver injury, and requires close blood count and liver monitoring throughout treatment.
Indication
Common therapeutic uses
- Temozolomide is used to treat adults with newly diagnosed glioblastoma multiforme, a type of brain tumour, given together with radiation therapy and then continued alone as maintenance treatment.
- Temozolomide is also used to treat adults with glioblastoma multiforme or anaplastic astrocytoma that has come back or progressed after standard treatment.
Pregnancy
Risk assessment and monitoring considerations
- Temozolomide has not been studied in pregnant women, but animal studies showed it can harm the developing fetus, so it should not be used during pregnancy unless the physician judges it clearly necessary.
- Women who could become pregnant should use effective contraception during treatment and for six months after stopping temozolomide.
Breastfeeding
Infant exposure considerations
- It is not known whether temozolomide passes into human breast milk, and breastfeeding should be stopped during treatment.
Geriatrics
Dosing and tolerability considerations
- Patients over 70 years of age appear to have a higher risk of neutropenia and thrombocytopenia (low white blood cell and platelet counts) compared with younger patients, so closer blood count monitoring is warranted.
Pediatrics
Use in children and adolescents
- Temozolomide has not been shown to be safe and effective in children, and Health Canada has not authorized its use in patients under 18.
Dosage & Administration
Practical dosing and administration
- For newly diagnosed glioblastoma, the concomitant phase uses a dose of 75 mg per square metre of body surface area daily for 42 days alongside radiation therapy, with weekly blood counts.
- After a 4-week break, maintenance treatment follows for up to 6 cycles: the first cycle uses 150 mg per square metre once daily for 5 days followed by 23 days off treatment.
- From the second maintenance cycle onward, the dose may be increased to 200 mg per square metre once daily for 5 days if blood counts and side effects from the first cycle allow it.
- For recurrent or progressive glioma in patients who have not had prior chemotherapy, the usual dose is 200 mg per square metre once daily for 5 days of a 28-day cycle.
- For recurrent or progressive glioma in patients who have had prior chemotherapy, treatment starts at 150 mg per square metre once daily for 5 days, increasing to 200 mg per square metre in the second cycle if blood counts allow.
- The dose is reduced or treatment is interrupted or stopped based on blood neutrophil and platelet counts and the severity of other side effects, as determined by the treating physician.
- Temozolomide should be taken on an empty stomach, at least one hour before a meal.
- If a dose is missed, or if vomiting occurs after taking a dose, the patient should contact their physician for instructions rather than taking an extra dose.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- A patient who took an overdose of 2,000 mg per day for 5 days developed pancytopenia (a severe drop in all blood cell types), fever, multi-organ failure, and died.
- Patients who have taken temozolomide for more than the prescribed 5 consecutive days, in some reported cases for weeks at a time, have developed severe and prolonged bone marrow suppression, sometimes with serious infection and death.
- Blood cell suppression is the main dose-limiting toxicity and is expected to be more severe with higher overdoses.
- There is no specific antidote; management of an overdose requires prompt blood count evaluation and supportive medical care.
Common side effects
Frequently reported tolerability concerns
- Nausea may occur, often improving with anti-nausea medication.
- Vomiting may occur.
- Constipation may occur.
- Diarrhea may occur.
- Loss of appetite may occur.
- Fatigue may occur, often significantly.
- Hair loss (alopecia) commonly occurs.
- Headache may occur.
- Skin rash may occur.
- Mouth or throat soreness (stomatitis) may occur.
- Altered taste may occur.
- Blurred vision may occur.
- Trouble sleeping may occur.
- Dry mouth or dry skin may occur.
- Itching may occur.
- Constipation and abdominal discomfort may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Temozolomide can severely suppress bone marrow function, causing low white blood cell counts (neutropenia) and low platelet counts (thrombocytopenia); in some cases this leads to prolonged pancytopenia and aplastic anemia, which has been fatal.
- Liver injury can occur, including rare cases of fatal liver failure; regular liver function blood tests are needed before and during treatment.
- Reactivation of hepatitis B infection has been reported and can be fatal, so patients are screened for hepatitis B before starting treatment.
- Herpes simplex encephalitis, a serious brain infection, has occurred, mainly in patients also receiving radiotherapy.
- Pneumocystis pneumonia, a serious lung infection, has occurred, particularly during the prolonged 42-day concomitant radiotherapy schedule, which is why preventive antibiotics are used during that phase.
- Inflammation of the lungs (pneumonitis) and lung scarring (pulmonary fibrosis) have been reported and can be fatal.
- Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported and can be fatal.
- A severe drug reaction with rash, fever, and organ involvement (DRESS syndrome) has been reported.
- Serious allergic reactions, including anaphylaxis, can occur.
- Seizures (convulsions) are common in patients with brain tumours and can occur or worsen during treatment.
- Bleeding, including cerebral hemorrhage, can occur, usually related to low platelet counts.
- Blood clots, including deep vein thrombosis and pulmonary embolism, have been reported.
- Secondary blood cancers, including myelodysplastic syndrome and leukemia, have occurred after temozolomide treatment.
- Diabetes insipidus (excessive thirst and urination from a hormone imbalance) has been reported.
- Seek urgent medical attention for fever, signs of infection, unusual bleeding or bruising, yellowing of the skin or eyes, severe skin blistering or peeling, new seizures, or sudden difficulty breathing.
Use with caution
Situations requiring closer assessment
- Use with caution, and only when benefits outweigh risks, in patients with poor overall health status, severe underlying illness, or active infection.
- Use with caution in patients with kidney impairment, as this has not been formally studied.
- Use with caution in patients with liver impairment, as this has not been formally studied.
- Use with caution in patients over 70, who have a higher risk of low blood cell counts.
- Use with caution in women, who have shown a higher rate of severe neutropenia and thrombocytopenia during the first treatment cycle.
- Use with caution in patients with a prior herpes simplex infection, who should be monitored for signs of brain infection.
- Use with caution in patients with current or past hepatitis B infection, who need monitoring for reactivation during and after treatment.
- Use with caution in patients also receiving corticosteroids, who should be watched closely for Pneumocystis pneumonia.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with a history of hypersensitivity to temozolomide or any ingredient in the capsules.
- Contraindicated in patients hypersensitive to dacarbazine, a chemically related chemotherapy drug.
- Not recommended in patients with severe bone marrow suppression at the start of treatment.
Drug interactions
Clinically relevant combinations
- Valproic acid can slightly reduce the clearance of temozolomide from the body, so combined use warrants caution.
- Combining temozolomide with other alkylating chemotherapy agents, such as bendamustine, carboplatin, or cisplatin, is likely to increase bone marrow suppression.
- No dose adjustment is needed when temozolomide is combined with the H2-blocker ranitidine.
- No dose adjustment is needed when temozolomide is combined with CYP3A-inducing drugs such as phenytoin, carbamazepine, or phenobarbital.
- No dose adjustment is needed when temozolomide is combined with dexamethasone.
- No dose adjustment is needed when temozolomide is combined with the anti-nausea drug prochlorperazine.
- Anti-nausea medication can be given before or after temozolomide doses without affecting its action.
Food interactions
Meal-related administration
- Temozolomide must be taken on an empty stomach, at least one hour before a meal, since food can reduce or delay its absorption.
Time of administration
Practical scheduling
- Temozolomide is taken once daily, at the same time each day of the treatment cycle, on an empty stomach at least one hour before eating.
Storage
Product handling
- Store temozolomide capsules between 15°C and 30°C, protected from moisture.
Patient take-away
Key counselling points for a quick closing summary
- Take temozolomide exactly as prescribed, on an empty stomach, at least one hour before a meal.
- Swallow the capsules whole with water; never open or chew them, since the contents are hazardous if they contact skin or are inhaled.
- If you miss a dose or vomit shortly after taking a dose, call your treatment team for instructions rather than taking an extra dose.
- You will need regular blood tests during treatment to check for low blood cell counts and liver problems.
- Use effective contraception during treatment and for six months afterward, whether you are male or female.
- Contact your treatment team right away for fever, signs of infection, unusual bleeding or bruising, yellow skin or eyes, severe rash or skin peeling, new seizures, or breathing difficulty.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.